Tempest kicks up a storm as Morpheus strikes again
Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.
ASCO 2023 – Morpheus spurs Roche to take the red pill
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.
